Experimental cell therapy takes on hard-to-treat throat cancer
NCT ID NCT04509726
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new type of cell therapy for people with advanced nasopharyngeal cancer linked to the Epstein-Barr virus. Nine patients received specially engineered immune cells (TCR-T cells) designed to recognize and attack the virus-infected cancer cells. The main goal was to find the safest dose, and the approach aims to improve treatment for solid tumors that are hard to control with standard therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Oncology, Xinqiao Hospital
Chongqing, Chongqing Municipality, 400037, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart T-Cell engager aims to outsmart tumors in first human test
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
- New radiation approach aims to reduce dry mouth in throat cancer patients
- New pill-chemo combo takes on hard-to-treat cancers
- Immune boosting duo takes on rare throat cancer